Metraipolis › archive › dc_005cfbd9c3f2

An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany — Europe PMC PMID:41477238

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41477238
DOI
10.3389/fpubh.2025.1667315
License (as archived)
solo-consultazione
Archived
2026-11-07T14:55:52.768Z
SHA-256 of the archived text
a1cb2fa2dffe35c1df7eef40a27f5b473c17bd799dcd14b4cacac536695c298c
Stable URL of this page
https://metraipolis.com/documento/dc_005cfbd9c3f2

How to cite

An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany — Europe PMC PMID:41477238 — Europe PMC (en), https://europepmc.org/article/MED/41477238 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_005cfbd9c3f2 (Metraipolis archive dc_005cfbd9c3f2, sha256 a1cb2fa2dffe35c1df7eef40a27f5b473c17bd799dcd14b4cacac536695c298c)
BibTeX
@misc{dc005cfbd9c3f2,
  title = {An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany — Europe PMC PMID:41477238},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41477238},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_005cfbd9c3f2; sha256 a1cb2fa2dffe35c1df7eef40a27f5b473c17bd799dcd14b4cacac536695c298c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41477238. Agents can read the archived copy with the MCP tool read_document.